Non-alcoholic fatty liver disease (NAFLD) refers to a wide range of liver conditions caused by the deposition of fat in liver. NAFLD primarily develops in stages. The first stage is fatty liver, which is harmless buildup of fat cells in the liver. The second stage, non-alcoholic steatohepatitis (NASH), is associated with inflammation and liver cell damage along with deposition of fat cells. Cirrhosis is the advanced stage which can cause permanent liver damage leading to liver failure. The common symptoms of non-alcoholic fatty liver disease are weakness, sudden weight loss, tiredness, and dull aching pain on the right side of stomach. NAFLD is diagnosed with liver function test and ultrasound scanning. People suffering from obesity, insulin resistance, high level of cholesterol, high blood sugar, and type 2 diabetes are more prone to non-alcoholic fatty liver disease. Rise in prevalence of obesity globally, surge in diabetes, increase in awareness about liver conditions in developing countries, high R&D funding, and rise in government initiatives are the major factors expected to drive the global non-alcoholic fatty liver disease drugs market. According to the American Diabetes Association, nearly 9% of the population of the U.S. is suffering from diabetes, the 7th leading cause of death in the country. According to data published by the World Health Organization (WHO), global obesity has tripled since 1975 and more than 650 million adults and 41 million children were obese in 2016. However, less availability of proper diagnostic facilities for treatment of the disease is likely to restrain the global market.
The global non-alcoholic fatty liver disease drugs market can be segmented based on product type, stage, and distribution channel. In terms of product type, the market can be classified into antioxidants, lipid lowering agents, thiazolidinedione, FXR receptor agonists, biguanides, and others. The biguanides segment held the largest share of the market in 2017 and is expected to sustain its leadership position during the forecast period due to its wide use in the management of non-alcoholic fatty liver disease. Based on stage, the global non-alcoholic fatty liver disease drugs market can be categorized into non-alcoholic steatohepatitis, fibrosis, and cirrhosis. The non-alcoholic steatohepatitis segment dominated the non-alcoholic fatty liver disease drugs market due to increase in prevalence of obesity. The segment is expected to sustain its leadership position in terms of market share during the forecast period. Based on distribution channel, the global market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the non-alcoholic fatty liver disease drugs market in 2017 and the trend is likely to continue from 2018 to 2026.
In terms of region, the global non-alcoholic fatty liver disease drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017 due to high prevalence of obesity and liver related disorders. According to the Trust for America’s Health, approximately 30% of the population of the U.S. suffers from non-alcoholic fatty liver disease and about 100 million are estimated to be affected with it. The non-alcoholic fatty liver disease drugs market in Asia Pacific is anticipated to expand at the highest CAGR owing to rise in prevalence of diabetes, surge in awareness, increase in per capita income, and improvement in health care infrastructure.
Major players operating in the global non-alcoholic fatty liver disease drugs market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Merck & Co., Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited., Allergan, Gilead, GW Pharmaceuticals plc, Cardax, Inc., and Novartis AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.
TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.
Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:
Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.
Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.
Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.